sangamo bags txcell, and a next- gen cell therapy tech ... · thalassemia, and hiv. but the company...
TRANSCRIPT
31/7/2018 Xconomy: Sangamo Bags TxCell, and a Next-Gen Cell Therapy Tech, for $84M
https://www.xconomy.com/san-francisco/2018/07/23/sangamo-bags-txcell-and-a-next-gen-cell-therapy-tech-for-84m/ 1/3
Register Now • Awards Gala →Xperience EXOME National Regions Channels Events Xpertise
all the information, none of the junk | biotech • healthcare • life sciences
Want EXOME sent to you daily?
[email protected] Sign Up
Meet the Contributors →
AD
VE
RTI
SE
ME
NT
Xconomy San Francisco —
Sangamo Bags TxCell, and a Next-Gen Cell Therapy Tech, for $84M
Sangamo Biosciences has acquired French biotechTxCell, adding an experimental technology with the potential to treat autoimmunediseases with cell therapy.
Sangamo (NASDAQ: SGMO), of Richmond, CA, will pay €72 million ($84.31million), or $2.58 per share, for TxCell. It expects to complete the deal laterthis year.
The deal gives Sangamo a technology that modifies regulatory T cells, or Tregs—a type of immune cell—to try to treat immunological diseases. The cell therapiesto win FDA approval thus far, known as CAR-T treatments, use a different typeof T cell and target blood cancers. TxCell’s approach hasn’t yet been tested inhumans, and the company didn’t have the cash to advance the technology on itsown, CEO Stephane Boissel said in a statement. “[It] would require expertise andfinancial resources that were impossible for us to get as a stand-alone business ata reasonable cost,” Boissel said.
The company had just €4.4 million in cash at the end of June and shares closedat €0 93 apiece on Friday Last week TxCell said in a statement it was working
UNDERWRITERS AND PARTNERS
Ben FidlerJuly 23rd, 2018 @benthefidler @xconomy Like Us
FROM OUR EDITORS · VIDEO
Interview with David Berryon MicrobiomeTherapeuticsVideo interview with David Berry,general partner at FlagshipPioneering.
XCONOMY INSIGHT · SPECIAL REPORT
Starting a Biotech Company:What Every EntrepreneurNeeds to KnowSuccess or failure depends on you. Getadvice from the experts to help your startup
XPERTISE: WATCH + LEARN
31/7/2018 Xconomy: Sangamo Bags TxCell, and a Next-Gen Cell Therapy Tech, for $84M
https://www.xconomy.com/san-francisco/2018/07/23/sangamo-bags-txcell-and-a-next-gen-cell-therapy-tech-for-84m/ 2/3
at €0.93 apiece on Friday. Last week, TxCell said in a statement it was workingon “securing a longer-term financing solution, such as a strategic partnershipand/or an equity offering.”
Sangamo is best known as a gene editing company, using an unproven approachknown as zinc finger nucleases to try to treat diseases like hemophilia, betathalassemia, and HIV. But the company has been expanding its work into otherdisease areas as well, and is increasingly trying to use gene editing to soup upcell therapies. In February, for instance, Gilead Sciences (NASDAQ: GILD)tapped Sangamo to try to use gene editing to develop next-gen CAR-T treatmentsfor cancer. The two could produce 10 or more possible products in the alliance ifall goes well.
Now Sangamo is trying a similar strategy with immunological conditions. As withits alliance with Gilead, Sangamo will use its gene editing technology alongsideTxCell’s cell therapies, known as CART-Tregs, hoping to develop effectivetreatments for multiple sclerosis and Crohn’s disease. The hope is these therapiesmight provide long-lasting effects with a single treatment. Sangamo will also testa CART-Treg treatment as an immunosuppressant following a solid organtransplant. (Here’s more on TxCell from Labiotech.eu)
Sangamo plans to begin a clinical trial in Europe next year testing CART-Tregs inorgan transplant patients.
Here’s more on Sangamo, gene editing, and its marriage with othertechnologies.
Ben Fidler is Xconomy's Deputy Biotechnology Editor. You can e-mail himat [email protected] Follow @benthefidler
Reprints
More From EXOME
Continuing Cell TherapyPush, Gilead Aligns withSangamo for CAR-T Boost
Pfizer Shells Out$14B to WinMedivation
Sweepstakes
Pfizer Shells Out $14B toWin MedivationSweepstakes
Protagonist, Janssen InkDevelopment Deal forCrohn’s Disease Drug
Trending on Xconomy
Epic Systems Pauses HQConstruction After 15Years of Constant Growth
Achaogen Restructures,Slashes Staff 28% asAntibiotic Launches
OUTBio, a BiopharmaLGBTQ Group, Grows Fast& Ponders Its Future
ADVERTISEMENT
ADVERTISEMENT
The Feed
EXOMEA Twitter list by @Xconomy
Innovators, entrepreneurs, journalists, and othernewsmakers in biotech healthcare & life sciences
advice from the experts to help your startupsucceed
Corporate Venture Capital ison the Rise in WisconsinCVC provides new funding source forstartups
WISCONSIN ECONOMIC DEVELOPMENT
CORPORATION
The Threat of a Black MarketWithin the MarketThe Hidden Risks of Sourcing HumanBiological Samples
SCIENTIST.COM
See How We’re Investing toChange Healthcare for theBetter.Providence Ventures shares its advice onmaking successful invest
PROVIDENCE VENTURES
FROM OUR ADVERTISERS